Drugs
Competition Problems in Prescription Drug Market
Although not the sole cause of high prescription drug costs, abusive practices that distort competition contribute to the problem. Too many companies exclude competition...
Preventing Drug Shortages and Saving Lives: The Role of Quality and Reliability Standards
Prescription drug shortages have become more common in recent years, interrupting usual medical care and increasing patient risk and system costs, but they are...
What Is the Price of a Prescription Drug?
Due to lack of transparency and mystery rebates, which are considered trade secrets, figuring out the price of a prescription drug is devilishly difficult....
Paid to Show the Drug Works: Why “Blind” Clinical Trials for New Drugs are Far Less Blind Than They Should Be
New research shows that physicians in industry-sponsored trials are more captured by pharmaceutical companies than physicians in unsponsored ones.
Economists love health care because it...
The Real Price of Health Data: Americans Don’t Want to Share Their Records for Free
The 2019 Chicago Booth/Kellogg School Financial Trust Index survey shows that 93 percent of participants don’t want to share their health data with digital...
The Rise of the Opioids: How Purdue Invented New Markets for OxyContin
Purdue's strategy was to market its opioids directly to patients via brochures, videos, advertisements, and the internet. It also provided information to doctors and...
The Generic Pharmaceutical Market Needs Competition. Non-Profits Can Provide It
JustMedicine is a non-profit that aims to introduce competition into the generic drug market by sponsoring generic entrants. The organization’s CEO explains why non-profit...
Perverse Market Incentives Encourage High Prescription Drug Prices
Pharmacy benefit managers (PBMs) are the under-discussed market participants who manage prescription drug insurance for the vast majority of Americans. PBMs claim to be a lone...
"The Pharmaceutical Industry Has a Large Amount of Control Over the Field of Oncology"
In the second part of our two-part interview with Daniel Goldstein, MD, an oncologist who studies the influence of business interests on healthcare, we talk...
When Medical Experiments Serve the Business Needs of Pharmaceutical Firms Instead of Science
The first part of a two-part interview with Daniel Goldstein, MD, an oncologist who also studies the influence of business interests on healthcare—from treating patients...
